- Home
- SHLS vs UPB Comparison
SHLS vs UPB Comparison
Compare SHLS & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHLS
- UPB
- Stock Information
- Founded
- SHLS 1996
- UPB 2021
- Country
- SHLS United States
- UPB United States
- Employees
- SHLS N/A
- UPB N/A
- Industry
- SHLS Semiconductors
- UPB
- Sector
- SHLS Technology
- UPB
- Exchange
- SHLS Nasdaq
- UPB NYSE
- Market Cap
- SHLS 778.5M
- UPB 622.8M
- IPO Year
- SHLS 2021
- UPB 2024
- Fundamental
- Price
- SHLS $4.63
- UPB $11.00
- Analyst Decision
- SHLS Buy
- UPB Strong Buy
- Analyst Count
- SHLS 21
- UPB 4
- Target Price
- SHLS $10.50
- UPB $56.50
- AVG Volume (30 Days)
- SHLS 6.4M
- UPB 442.0K
- Earning Date
- SHLS 02-26-2025
- UPB 02-14-2025
- Dividend Yield
- SHLS N/A
- UPB N/A
- EPS Growth
- SHLS N/A
- UPB N/A
- EPS
- SHLS 0.19
- UPB N/A
- Revenue
- SHLS $422,657,000.00
- UPB $2,207,000.00
- Revenue This Year
- SHLS N/A
- UPB N/A
- Revenue Next Year
- SHLS $11.57
- UPB N/A
- P/E Ratio
- SHLS $23.85
- UPB N/A
- Revenue Growth
- SHLS N/A
- UPB 82.10
- 52 Week Low
- SHLS $4.07
- UPB $10.36
- 52 Week High
- SHLS $17.50
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- SHLS 38.98
- UPB N/A
- Support Level
- SHLS $4.37
- UPB N/A
- Resistance Level
- SHLS $6.11
- UPB N/A
- Average True Range (ATR)
- SHLS 0.37
- UPB 0.00
- MACD
- SHLS -0.15
- UPB 0.00
- Stochastic Oscillator
- SHLS 12.81
- UPB 0.00
About SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.